Screening of gestational diabetes mellitus in early pregnancy by oral glucose tolerance test and glycosylated fibronectin: study protocol for an international, prospective, multicentre cohort trial by Huhn, E A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Screening of gestational diabetes mellitus in early pregnancy by oral glucose
tolerance test and glycosylated fibronectin: study protocol for an
international, prospective, multicentre cohort trial
Huhn, E A; Fischer, T; Göbl, C S; Todesco Bernasconi, M; Kreft, M; Kunze, M; Schoetzau, A;
Dölzlmüller, E; Eppel, W; Husslein, P; Ochsenbein-Koelble, N; Zimmermann, R; Bäz, E; Prömpeler, H;
Bruder, E; Hahn, S; Hoesli, I
Abstract: INTRODUCTION: As the accurate diagnosis and treatment of gestational diabetes mellitus
(GDM) is of increasing importance; new diagnostic approaches for the assessment of GDM in early preg-
nancy were recently suggested. We evaluate the diagnostic power of an ’early’ oral glucose tolerance test
(OGTT) 75 g and glycosylated fibronectin (glyFn) for GDM screening in a normal cohort. METHODS
AND ANALYSIS: In a prospective cohort study, 748 singleton pregnancies are recruited in 6 centres in
Switzerland, Austria and Germany. Women are screened for pre-existing diabetes mellitus and GDM by
an ’early’ OGTT 75 g and/or the new biomarker, glyFn, at 12-15 weeks of gestation. Different screening
strategies are compared to evaluate the impact on detection of GDM by an OGTT 75 g at 24-28 weeks
of gestation as recommended by the International Association of Diabetes and Pregnancy Study Groups
(IADPSG). A new screening algorithm is created by using multivariable risk estimation based on ’early’
OGTT 75 g and/or glyFn results, incorporating maternal risk factors. Recruitment began in May 2014.
ETHICS AND DISSEMINATION: This study received ethical approval from the ethics committees in
Basel, Zurich, Vienna, Salzburg and Freiburg. It was registered under http://www.ClinicalTrials.gov
(NCT02035059) on 12 January 2014. Data will be presented at international conferences and published
in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT02035059.
DOI: 10.1136/bmjopen-2016-012115
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-128758
Published Version
 
 
Originally published at:
Huhn, E A; Fischer, T; Göbl, C S; Todesco Bernasconi, M; Kreft, M; Kunze, M; Schoetzau, A; Dölzlmüller,
E; Eppel, W; Husslein, P; Ochsenbein-Koelble, N; Zimmermann, R; Bäz, E; Prömpeler, H; Bruder, E;
Hahn, S; Hoesli, I (2016). Screening of gestational diabetes mellitus in early pregnancy by oral glucose
tolerance test and glycosylated fibronectin: study protocol for an international, prospective, multicentre
cohort trial. BMJ Open, 6(10):e012115. DOI: 10.1136/bmjopen-2016-012115
Screening of gestational diabetes
mellitus in early pregnancy by oral
glucose tolerance test and glycosylated
ﬁbronectin: study protocol for an
international, prospective, multicentre
cohort trial
E A Huhn,1 T Fischer,2 C S Göbl,3 M Todesco Bernasconi,4 M Kreft,5 M Kunze,6
A Schoetzau,1 E Dölzlmüller,2 W Eppel,3 P Husslein,3 N Ochsenbein-Koelble,5
R Zimmermann,5 E Bäz,6 H Prömpeler,6 E Bruder,7 S Hahn,8 I Hoesli1
To cite: Huhn EA, Fischer T,
Göbl CS, et al. Screening of
gestational diabetes mellitus
in early pregnancy by oral
glucose tolerance test and
glycosylated fibronectin:
study protocol for an
international, prospective,
multicentre cohort trial. BMJ
Open 2016;6:e012115.
doi:10.1136/bmjopen-2016-
012115
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
012115).
Received 7 April 2016
Revised 13 July 2016
Accepted 24 August 2016
For numbered affiliations see
end of article.
Correspondence to
Dr EA Huhn;
evelyn.huhn@usb.ch
ABSTRACT
Introduction: As the accurate diagnosis and treatment
of gestational diabetes mellitus (GDM) is of increasing
importance; new diagnostic approaches for the
assessment of GDM in early pregnancy were recently
suggested. We evaluate the diagnostic power of an
‘early’ oral glucose tolerance test (OGTT) 75 g and
glycosylated fibronectin (glyFn) for GDM screening in a
normal cohort.
Methods and analysis: In a prospective cohort
study, 748 singleton pregnancies are recruited in 6
centres in Switzerland, Austria and Germany. Women
are screened for pre-existing diabetes mellitus and
GDM by an ‘early’ OGTT 75 g and/or the new
biomarker, glyFn, at 12–15 weeks of gestation.
Different screening strategies are compared to evaluate
the impact on detection of GDM by an OGTT 75 g at
24–28 weeks of gestation as recommended by the
International Association of Diabetes and Pregnancy
Study Groups (IADPSG). A new screening algorithm is
created by using multivariable risk estimation based on
‘early’ OGTT 75 g and/or glyFn results, incorporating
maternal risk factors. Recruitment began in May 2014.
Ethics and dissemination: This study received
ethical approval from the ethics committees in Basel,
Zurich, Vienna, Salzburg and Freiburg. It was
registered under http://www.ClinicalTrials.gov
(NCT02035059) on 12 January 2014. Data will be
presented at international conferences and published in
peer-reviewed journals.
Trial registration number: NCT02035059.
INTRODUCTION
Gestational diabetes mellitus (GDM) is
deﬁned as diabetes diagnosed during preg-
nancy that is not clearly overt diabetes.1 The
increasing number of women with
undiagnosed type 2 diabetes mellitus (T2DM)
in pregnancy has led to the recommendation
of screening women with risk factors for pre-
existing diabetes at the ﬁrst antenatal visit.
GDM is still diagnosed in the late second or
early third trimester, because accurate diag-
nostic approaches for GDM assessment in ﬁrst
trimester are still lacking.2
GDM is associated with adverse maternal
and perinatal outcomes, such as fetal over-
growth, shoulder dystocia, operative delivery,
birth injury, pre-eclampsia, haemorrhage and
preterm delivery,3–5 but also a sevenfold
higher risk of the mother developing T2DM
after pregnancy.6 In addition, the maternal
metabolic milieu was also identiﬁed as a key
Strengths and limitations of this study
▪ This is an international, prospective, multicentre
cohort trial recruiting at six centres in
Switzerland, Austria and Germany.
▪ It is the first study to assess an ‘early’ oral
glucose tolerance test 75 g and novel biomarkers
like glycosylated fibronectin for screening of ges-
tational diabetes mellitus in early pregnancy.
▪ The recruitment of 748 pregnant women is
planned. We have designed the study to be suffi-
ciently powered to compare the different early
screening approaches with the detection of ges-
tational diabetes mellitus at 24–28 weeks of
gestation.
▪ This study may be underpowered for the evalu-
ation of neonatal outcomes like large for gesta-
tional age infants, neonatal hypoglycaemia,
shoulder dystocia or birth trauma (secondary
outcomes).
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determinant for the susceptibility to obesity, metabolic
syndrome and T2DM in the offspring,7 a phenomenon
often described as ‘fetal programming’.
The current—but still widely discussed—standard of
care in GDM screening is the oral glucose tolerance test
(OGTT) of 75 g glucose performed late at 24–28 weeks
of gestation as recommended by the International
Association of Diabetes and Pregnancy Study Groups
(IADPSG).8 The new screening thresholds are based on
the results of a large prospective cohort multicentre trial,
the Hyperglycaemia and Adverse Pregnancy Outcome
(HAPO) study.4 The aim of the HAPO study was to associ-
ate the degree of maternal glycaemia with adverse peri-
natal outcome, such as large for gestational age (LGA)
infants, neonatal hypoglycaemia and caesarean section
rates. The results showed no obvious threshold, but
rather a continuous increase of these adverse outcomes
across the range of glucose concentrations. The IADPSG
criteria resulted in a considerable increase in GDM preva-
lence of 17.8%, a detection rate of 83% for adverse
outcome and a positive predictive value of 16%.8
An early and rapid diagnosis of GDM even before
24 weeks of gestation is desirable. By targeted early inter-
vention including physical activity, moderate diet or
insulin/drug therapy starting in the ﬁrst trimester, rates
of macrosomia (birth weight >4000 g) or LGA
(LGA=birth weight >90th centile) infants, operative
vaginal delivery and perinatal morbidity could be pos-
sibly reduced. Moreover, there could be a long-term
downstream effect on the offspring, thereby leading to
considerable savings in healthcare costs by possibly
decreased prevalence of generational transmission of
metabolic diseases. But further research is necessary to
evaluate the effects of an early intervention on short-
term and long-term outcomes for mother and child.
We propose that an ‘early’ OGTT combined with
maternal history, maternal condition and promising new
biomarkers such as glycosylated ﬁbronectin (glyFn)
could diagnose similarly GDM, even in the ﬁrst trimes-
ter. Rasanen et al published a study in September 2013
introducing glyFn as a new early GDM screening
approach with an area under the curve (AUC) of 0.91
and 95% CI of 0.87 to 0.96, a positive predictive value of
63% and a negative predictive value of 95%. Although
some predictors of GDM have been studied retrospect-
ively, no study to date has considered the use of promis-
ing new biomarkers combined with an ‘early’ OGTT and
maternal risk factors evaluation in ﬁrst trimester of
pregnancy.
STUDY OBJECTIVES
Primary objective
The use of the ‘early’ OGTT 75 g and/or the new bio-
marker, glyFn, as a new screening approach in late ﬁrst/
early second trimester will be evaluated and compared
with GDM diagnosis by OGTT 75 g at 24–28 weeks of
gestation.
Secondary objectives
1. A new screening algorithm will be created by using
multivariable risk estimation based on ‘early’ OGTT
75 g and/or glyFn results, incorporating maternal
risk factors.
2. The signiﬁcance of the association between glyFn,
‘early’ OGTT 75 g and maternal body mass index
and/or clinical conditions including chronic hyper-
tension, pregnancy-induced hypertension or pre-
eclampsia and fetal conditions such as intrauterine
growth restriction will be evaluated.
METHODS
This study protocol was developed on the basis of
Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT; see online supplementary
‘SPIRIT checklist’ for further details).
Study settings/design
This is an international, prospective, multicentre cohort
trial conducted at one secondary and ﬁve tertiary refer-
ral centres in Switzerland, Austria and Germany. Study
recruitment started primarily at the coordination centre
at University Hospital Basel on 1 May 2014. All other
centres started recruitment consecutively until the end
of March 2016. Recruitment is expected to last until
December 2017 (see ﬁgure 1 for details about the
expected time frame). The aim is to enrol 748 women at
12–15 weeks of gestation with a minimum recruitment
of 50 women planned for each centre depending on
size and time of recruitment (Aarau: n=50, Basel: n=358,
Freiburg: n=60, Salzburg: n=100, Vienna: n=100, Zurich:
n=80). Fifty per cent of eligible women are expected to
accept participation. The trial was registered under
http://www.ClinicalTrials.gov under NCT02035059 on
12 January 2014.
Recruitment and informed consent
Participants are identiﬁed at their ﬁrst antenatal visit
between 6 and 15 weeks of gestation. The investigator or
obstetrician in charge informs the women about all
aspects pertaining to the trial. The informed consent
includes permission for gathering data from medical
records and the optional storage of blood for a
maximum of 10 years for additional analyses related to
the current study. Participants are informed that trial
participation is voluntary and that they are free to with-
draw without any effects on subsequent care. All
members of the research team are aware of the guide-
lines for good clinical practice for obtaining consent.9
Eligibility criteria
Inclusion criteria are
▸ Women at least 18 years of age and not under
guardianship;
▸ Healthy singleton pregnancy after spontaneous con-
ception or after fertility treatment;
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▸ Six to 15 weeks of gestation;
▸ Signed informed consent.
Exclusion criteria are
▸ Previous bariatric surgery;
▸ Known pre-existing diabetes mellitus or under treat-
ment with metformin;
▸ Known chronic infection like hepatitis or HIV or
chronic kidney, liver or heart disease;
▸ Known maternal history of hypertensive diseases in a
previous pregnancy and now under prophylactic acet-
ylsalicylate treatment;
▸ Fetal genetic, chromosomal or intervention-requiring
morphological abnormalities;
▸ The inability to read and/or understand the partici-
pant’s information sheet.
Study procedure
All healthy pregnant patients with regular care at the
participating hospitals are counselled and asked at 6–15
weeks of gestation to participate. At 10+0 to 13+6 weeks
of gestation, all women have to undergo a ﬁrst trimester
ultrasound scan which is standard care at participating
sites. The ultrasound scan is used to conﬁrm gestational
age, diagnose any major fetal abnormalities and option-
ally measure fetal nuchal translucency thickness, which
together with maternal free β-chorionic gonadotropin
and pregnancy-associated plasma protein A, is used for
screening for chromosomal abnormalities. In addition, if
informed consent had been given during the ﬁrst ante-
natal visit or at the time of the ﬁrst trimester scan, the
maternal history and condition are assessed, and blood
for biomarker analysis and for the ‘early’ OGTT 75 g is
drawn at the study visit at 12–15 weeks of gestation. The
‘early’ OGTT 75 g is compared with plasma glucose
results obtained at 24–28 weeks of gestation after the
OGTT 75 g. No additional visit is necessary besides the
standard routine antenatal care visits.
GlyFn and ‘early’ OGTT 75 g
All participants are instructed to fast for at least 10 hours
before sampling. Two fasting glucose samples are taken.
One sample is collected for storage of two aliquots
(2×1 mL) at −80°C for later analysis of glyFn and
another sample for the fasting plasma glucose (FPG)
value. After intake of the 75 g glucose load, blood
samples are drawn 60 and 120 min later for the determin-
ation of glucose levels. Plasma glucose is measured by an
automated colorimetric-enzymatic method (hexokinase/
glucose-6-phosphate-dehydrogenase) on a Hitachi/Roche-
Modular P analyser. GlyFn will be analysed as previously
reported by Rasanen et al10 (monoclonal glyFn antibody)
Figure 1 Expected time frame.
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by DiabetOmics, Beaverton, Oregon, USA. The maternal
glyFn and ‘early’ OGTT 75 g results are blinded to the
investigators.
Unblinding
Values will be unblinded if the FPG levels are
≥7.0 mmol/L or the 2-hour plasma glucose levels are
≥11.1 mmol/L, suggesting pre-existing diabetes melli-
tus.11 The diagnosis of pre-existing diabetes mellitus
needs to be conﬁrmed by an elevated glycosylated
haemoglobin (HbA1c) value ≥6.5%. Plasma glucose
levels of ≤2.5 mmol/L are also abnormal and require
further clariﬁcation. Women with conﬁrmed pre-existing
diabetes mellitus are treated according to a standardised
protocol in line with current recommendations.
Study outcomes
Diagnosis of GDM
GDM is diagnosed if at least one value of the 75 g OGTT
at 24–28 weeks of gestation exceeds the recommended
IADPSG threshold: FPG of ≥5.1 mmol/L (92 mg/dL),
1-hour glucose of ≥10.0 mmol/L (180 mg/dL) and
2-hour glucose of ≥8.5 mmol/L (153 mg/dL). All
women who screen positive are followed up by a nutri-
tionist and a diabetic nurse in contact with a diabetolo-
gist, and have frequent regular appointments in our
obstetrical outpatient clinic in 2–4 weeks intervals
depending on clinical condition, glucose values and
ultrasound scan ﬁndings. Women who fail to meet the
target glucose values after 1–2 weeks of diet management
are treated with insulin according to the guidelines of the
Swiss Society for Endocrinology and Diabetology
(SGED), the Austrian Diabetes Association (ÖDG), the
German Diabetes Association (DDG) and the German
Association of Gynaecology and Obstetrics (DGGG).12–14
The glycaemic targets, insulin therapy, dose adjustments,
concomitant medication and/or supplements are
recorded.
Pregnancy, delivery and neonatal outcome data
Maternal data such as pre-eclampsia (blood pressure
(BP) ≥140/90 mm Hg >20 weeks of gestation with pro-
teinuria), pregnancy-induced hypertension (BP≥140/
90 mm Hg >20 weeks of gestation, rate of sonographic
estimated polyhydramnios (amniotic ﬂuid index
≥25 cm) or LGA (estimated birth weight ≥90th centile),
delivery outcome including delivery mode (spontaneous
vaginal, forceps, vacuum, planned caesarean section or
during labour) and indication, and neonatal outcome
data such as birth weight, rate of LGA (birth weight
≥90th centile), preterm birth ≤37 completed weeks of
gestation, 5 and 10 min Apgar scores, arterial umbilical
cord pH≤7.0, shoulder dystocia, birth trauma, neonatal
hypoglycaemia (glucose value of <2.5 mmol/L in infants
born ≥34 weeks of gestation), jaundice (transcutaneous
bilirubin >95th centile or need of phototherapy at any
time after delivery), respiratory distress syndrome,
congenital anomalies and admission to intensive care
unit are prospectively collected.
Statistics
Sample size justification
We aim to demonstrate that the recently reported bio-
marker, glyFn and/or the ‘early’ OGTT 75 g at 12–15
weeks of gestation has sufﬁcient diagnostic power to
evaluate women at risk of developing GDM compared
with the OGTT 75 g at 24–28 weeks of gestation. The
receiver operator characteristic (ROC) curve of glyFn
has a reported AUC of 0.91 (95% CI 0.87 to 0.96).15
The OGTT 75 g screening test using the IADPSG cri-
teria has not been tested in early pregnancy so far. The
FPG value in early pregnancy has an AUC of 0.61 (95%
CI 0.54 to 0.68) compared with IADPSG criteria in later
pregnancy in a retrospective study.16 We assume—
according to data from the centre in Basel17—that
around 0.6% of recruited women will be diagnosed with
pre-existing diabetes mellitus by the ‘early’ OGTT 75 g.
The prevalence of GDM is assumed to be around 10.9%
according to a current IADPSG screening study from
various Swiss laboratories.18 The new screening
approach should have a proposed true AUC of 0.9 with
a lower boundary of 0.8 (95% CI >0.8) which would lead
to a power of 90% and an α-level of 5% to an estimated
sample size of 650 (65 women with GDM, 585 women
without GDM). This power calculation is valid for
OGTT, glyFn or combined markers. It ensures that the
AUC is estimated with good precision regardless of the
chosen biomarker or any combination. Offsetting a
dropout of 15% leads to a total sample size of 748. The
dropout rate is expected to be equally distributed
between centres. A sample size review will be performed
after the ﬁrst 300 recruitments. The power calculation
was performed using MedCalc V.15.11 2015.19
Statistical analysis plan
Descriptive statistics and graphical examination will be
performed for all primary and secondary study variables.
Primary objective
In order to predict GDM, ROC curves with correspond-
ing AUCs will be calculated separately for glyFn and the
‘early’ OGTT 75 g. GDM diagnosis by OGTT 75 g at 24–
28 weeks of gestation is considered a routine method.
AUCs will be estimated with a 95% CI.
Secondary objectives
Logistic regression will allow combining glyFn, the
‘early’ OGTT and maternal risk factors in a multivariable
risk model. Subsequent AUC will be calculated with 95%
CI. Results will be internally cross-validated to prevent
overoptimistic results. Optimal cut-off points to predict
GDM will be determined based on these ROC curve.
Sensitivity, speciﬁcity, positive and negative predictive
values will also be estimated with 95% CI. However, other
‘machine learning’ algorithms could be better than
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logistic regression. Therefore, other popular procedures
will be additionally tested: random forest and penalised
logistic regression (Lasso). Details are described in Hastie
et al.20 Predictive performances will be internally cross-
validated and explored in examining AUC of the ROC
and predicted versus observed probabilities. Random
forest and penalised logistic regression avoid overﬁtting
(to certain extent) whereas logistic regression does not.
Random forest will be chosen because of its popularity
and good benchmark results. Lasso is known for its good
interpretability. Logistic regression will probably show its
inferiority compared with the other methods. Internal
cross-validation will be carried out using the package ‘mlr’
within R. Internal cross-validation (eg, 10-fold) is a good
possibility to estimate the ﬁtting on a potential future data
set. Based on these results, it will be decided whether a
new prediction model for GDM will be proposed. In
order to potentially improve the primary study variables,
secondary study parameters such as changes in maternal
body mass index (BMI) and/or clinical conditions like
chronic hypertension and pregnancy-induced hyperten-
sion or pre-eclampsia and fetal conditions including intra-
uterine growth restriction will be added to the machine
learning models. Statistical analyses will be performed and
graphs will be plotted using the current version of the stat-
istical computation program R (R Development Core
Team R. R: A Language and Environment for Statistical
Computing. R Found Stat Comput 2014;1:409).
Data recording
Each participant receives an identiﬁcation number to
ensure conﬁdentiality and the collected data are exchanged
between centres using only the identiﬁcation number. The
name and birth date of each participant are stored with a
different identiﬁcation number in order to preserve the
possibility to look for inconsistencies during the study.
Reporting of adverse events
Any (serious) adverse events (AE/SAE) are recorded by
the investigator using the speciﬁc AE/SAE sheet of the
clinical report form. All SAE are reported to the respon-
sible ethics committee within an appropriate time frame.
OTHER STUDY MEASUREMENTS
Other biomarkers
An extensively studied biomarker for early GDM screen-
ing is adiponectin.21–23 Adiponectin is an adipocyte-
derived hormone and reﬂects whole body insulin sensi-
tivity.24 A recently published meta-analysis calculated a
summary sensitivity of 60.3% and a speciﬁcity of 81.3%
with an AUC of 0.79.22 Maternal serum adiponectin con-
centration is measured by a quantitative sandwich ELISA
technique. Another potential biomarker is pregnancy-
speciﬁc glycoprotein-1 (PSG-1).25 PSG-1 had a detection
rate of 74% with a false-positive rate of 6% and an AUC
of 0.81. PSG-1 is analysed as previously reported by
Nagalla et al25 by DiabetOmics, Beaverton, Oregon, USA.
Evaluation of insulin and HbA1c
At the early study visit at 12–15 weeks of gestation,
insulin, C peptide and HbA1c are additionally measured
from the fasting blood sample in all women. HbA1c is
measured by reversed-phase cation exchange chromatog-
raphy (ADAMS HA-8160, Menarini Diagnostics Benelux,
Zaventem, Belgium) or high performance liquid chroma-
tography with Variant II, Bio-Rad (International
Federation of Clinical Chemistry (IFCC) standardised
and Diabetes Control and Complications Trial (DCCT)
aligned with coefﬁcient of variation (CV) 1.8% for
HbA1c=5.6%). Insulin is measured by chemilumines-
cence immunoassay (CLIA; Roche Modular E170, Basel,
Switzerland). The homoeostasis model assessment of
insulin resistance or the Quantitative Insulin Sensitivity
Check Index (QUICKI) is used as an approximate of
fasting (ie, hepatic) insulin resistance.26 27 The β-cell
function is assessed from fasting glucose and insulin levels
according to Wallace et al.26
Measurement of vitamin D
Vitamin D deﬁciency is associated with inhibited insulin
secretion, insulin resistance and β-cell dysfunction in the
pancreas in T2DM.28 29 Additionally, vitamin D has im-
munomodulatory properties which protects against the
development of T1DM. Supplementation of 1,25-OH
vitamin D seems to alter T cells composition and reduces
cytokine-induced apoptosis of pancreatic islet cells.30 31
We would like to have the actual values for 25-OH
vitamin D and it will be evaluated in this cohort by CLIA
(Liaison, DiaSorin, Saluggia, Italy).
Influence of stress in early pregnancy on development of
GDM
Psychological factors in early pregnancy might contrib-
ute to adverse obstetric outcome.32 This trial investigates
the inﬂuence of perceived stress, stressful life events and
depression on the development of GDM. The participants
recruited in Basel are therefore asked to collect salivary
samples for cortisol directly at the time of waking up, at
30 and at 60 min after waking up. The saliva samples are
stored at −20°C until analysis. After thawing, the saliva
samples are centrifuged. Cortisol levels are determined
using a competitive solid phase time-resolved ﬂuorescence
immunoassay with ﬂuorometric end point detection
(DELFIA).33 Copeptin is a more stable precursor
hormone of arginine–vasopressin and is found to be ele-
vated in many diseases.34–37 This effect can be attributed
to the response of the hypothalamic–pituitary–adrenal
axis to psychological stress. Copeptin will be measured in
the fasting blood sample with time-resolved ampliﬁed
cryptate emission technology (TRACE) by BRAHMS
Kryptor Compact immunoanalyser from Thermo
Scientiﬁc Brahms GmbH, Henningsdorf, Germany.
Three self-administered questionnaires are obtained at
the study visit at 12–15 weeks of gestation:
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Questionnaire on perceived stress
The perceived stress scale is a 10-item inventory for
measuring the perception of stress.38 It is widely used
and has been validated in pregnancy.39
Questionnaire on stressful life events
The Holmes and Rahe Stressful Life Events Scale
(SLE)40 is a 43-item instrument for the evaluation of
stressful experiences during the past 12 months prior to
answering the questionnaire.
Questionnaire on depression
The 10-item Edinburgh Postnatal Depression Screen
(EPDS)41 is used to assess symptoms of depression
during the past 7 days. It has been widely validated in
pregnancy42 43 and is a part of the standard evaluation
of pregnant women attending routine prenatal visits at
the University Hospital in Basel. Scores ≥13 indicate at
least probable minor depression and scores ≥15 indi-
cated probable major depression. Pregnant women with
scores ≥13 are routinely offered psychological or psychi-
atric counselling during pregnancy.
Histological examination of the placenta
The fetal nutrients supply is regulated by maternal–fetal
glucose and lipid concentration, placental blood ﬂow
and trophoblastic nutrient transporters.44 The placenta
reacts with adaptive changes in structure and functions to
a hyperglycaemic milieu.45 These changes of the placenta
will be assessed depending on the maternal glycaemic
control by standard pathology examination.46
DISCUSSION
To the best of our knowledge, this is the ﬁrst large
European cohort study that prospectively evaluates the
promising new biomarker, glyFn, and the ‘early’ OGTT
75 g by comparing the impact of different GDM screen-
ing strategies with IADPSG criteria at 24–28 weeks of ges-
tation. The IADPSG criteria have not been tested
prospectively in early pregnancy, despite the suggestion
of the IADPSG consensus panel in 20108 to take a FPG
value ≥5.1 mmol/L as a cut-off value for GDM. This rec-
ommendation was based on a retrospective study observ-
ing that high ﬁrst trimester FPG in early pregnancy was
associated with adverse pregnancy outcome.47 We
propose that glyFn with FPG alone or in combination
with postload glucose values should at least result in an
AUC of 0.8 compared with the OGTT 75 g in later preg-
nancy. Rasanen et al15 could show that glyFn was inde-
pendent of maternal age, parity, gestational age, the
time of sample collection and the administration of the
OGTT at 24–28 weeks of gestation. The current trial
might clarify whether glyFn is dependent on maternal
BMI or clinical conditions such as chronic hypertension,
pregnancy-induced hypertension or the development of
pre-eclampsia or intrauterine growth restriction.
The screening approach combining glyFn±FPG could
overcome some problems of the OGTT. First, OGTT is
time consuming. GlyFn and FPG alone can be drawn in
a fasting state of the women in early morning and the
women do not have to wait further. Second, OGTT is
inconvenient to administer and some women suffer
intolerance to the glucose load resulting in nausea and
vomiting. No glucose administration would be necessary
with a screening method combining glyFn and FPG.
Third, we propose that glyFn might overcome the
problem of low reproducibility like the OGTT. Like
HbA1c, glyFn might also assess long-term serum glucose
concentration. But this is hypothetical and needs to be
proven. Additionally, we suppose that a multivariable
prediction model incorporating risk factors, that is,
maternal age and/or BMI, together with glyFn and/or
FPG and postload glucose values might improve risk
stratiﬁcation in early pregnancy and could possibly
decrease the required OGTTs later in pregnancy.
In the current study, the diagnostic power of glyFn will
be evaluated using serum samples. But glyFn can be ana-
lysed additionally out of a dried blood stain. The result-
ing test is affordable (ie, estimated costs in India are US
$2–US$3/dried blood spot, in Europe US$20–US$30/
serum sample), which would help especially developing
countries that suffer particularly from problems with the
implementation of the IADPSG recommendations,48 to
beneﬁt from a possibly simple and cheap screening tool
for GDM. The analysis of glyFn in dried blood is not
part of this trial and needs to be validated separately in
future studies.
Cost-effectiveness analyses of IADPSG criteria using
decision analysis models showed that the one-step screen-
ing with OGTT 75 g might be cost-effective when postde-
livery care would reduce the development of T2DM in
the mothers.49 50 Another study reported cost-
effectiveness if pre-eclampsia would decrease to >0.55%
and caesarean delivery rate would fall to >2.7%.51 A new
screening in the ﬁrst trimester could be cost-effective if
the method would reduce ﬁrst the 1 and 2 hours blood
sampling and/or second would decrease laboratory work-
load by avoiding a second screening in 24–28 weeks of
gestation. Additionally, the newfound screening approach
could result in the identiﬁcation of women with overt dia-
betes or/and GDM in the ﬁrst trimester. The aim of an
early GDM diagnosis is the start of timely intervention
with diet, exercise or—if necessary—insulin therapy in
early second trimester. Earlier treatment potentially
should result in the reduction of neonatal and maternal
morbidities, that is, physical exercise reduces total mater-
nal weight gain and the rate of GDM.52 However, there is
still a paucity of randomised-controlled interventional
trials showing that diagnosis and treatment of
GDM<24 weeks of gestation improve pregnancy out-
comes. Until the efﬁcacy of early treatment is not studied
and veriﬁed thoroughly, cost-effectiveness analysis will be
of restricted value, but a cost analysis could be performed
assuming different outcome scenarios.
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One limitation of our trial is that it is not powered
for the evaluation of neonatal outcomes like LGA
infants, neonatal hypoglycaemia, shoulder dystocia or
birth trauma (these are planned secondary out-
comes). The study would need to be signiﬁcantly
larger to detect effects on these neonatal outcomes. If
this trial were to show positive diagnostic power for
the new screening algorithm, a large multicentre
study may be required to be sufﬁciently powered to
determine the algorithm’s effect on the rate of LGA
infants or neonatal hypoglycaemia as proposed in the
HAPO study.4
Finally, the glyFn assay is not yet commercially avail-
able and will be performed by DiabetOmics, Beaverton,
Oregon, USA. For a widespread implementation of the
ﬁnally proposed screening approach, a standardisation
between laboratories will be necessary ﬁrst.
The results of our study may have a major impact on
future screening approaches for GDM by the develop-
ment of a potentially simple, cost-effective and for the
pregnant women a comfortable screening method for
GDM in the ﬁrst trimester.
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